<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019864</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067263</org_study_id>
    <secondary_id>NCI-99-C-0125I</secondary_id>
    <nct_id>NCT00019864</nct_id>
    <nct_alias>NCT00001821</nct_alias>
  </id_info>
  <brief_title>Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma</brief_title>
  <official_title>Osteosarcoma: Outcome of Therapy Based on Histologic Response. A Collaborative Effort of the POB/NCI, Texas Children's Hospital and University of Oklahoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Giving chemotherapy before surgery may shrink the tumor so that it&#xD;
      can be removed during surgery. Giving chemotherapy after surgery may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving chemotherapy before and after&#xD;
      surgery works in treating patients with osteosarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the rate of in vivo histologic response in patients with osteosarcoma treated&#xD;
           with neoadjuvant cisplatin, methotrexate, and doxorubicin with dexrazoxane (as&#xD;
           cardioprotection).&#xD;
&#xD;
        -  Determine the event-free and overall survival of patients with nonmetastatic disease who&#xD;
           show good response to neoadjuvant therapy and receive adjuvant therapy with the same&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the event-free survival of patients with nonmetastatic disease who show poor&#xD;
           response to neoadjuvant therapy and receive adjuvant therapy with the same regimen.&#xD;
&#xD;
        -  Determine the event-free survival and overall survival of patients with metastatic&#xD;
           disease who receive neoadjuvant therapy.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Neoadjuvant therapy: Patients receive neoadjuvant chemotherapy comprising dexrazoxane IV&#xD;
           over 15 minutes, doxorubicin IV over 15 minutes, and cisplatin IV over 4 hours on days 1&#xD;
           and 2 in week 0. Patients also receive methotrexate IV over 4 hours followed by&#xD;
           leucovorin calcium in weeks 3 and 4. Patients then receive filgrastim (G-CSF)&#xD;
           subcutaneously (SC) once daily beginning 24 hours after completion of chemotherapy and&#xD;
           continuing until blood counts recover. Treatment repeats every 5 weeks for 2 courses in&#xD;
           the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Surgical resection: Patients undergo definitive surgery in week 11.&#xD;
&#xD;
        -  Adjuvant therapy: Patients receive dexrazoxane, doxorubicin, cisplatin, methotrexate,&#xD;
           and leucovorin calcium as in neoadjuvant therapy*. Treatment repeats every 5 weeks for&#xD;
           up to 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      NOTE: *Cisplatin is not administered in courses 3 and 4 of adjuvant therapy&#xD;
&#xD;
      Patients are followed within 4 weeks, every 3 months for 2 years, every 6 months for 2 years,&#xD;
      and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 100 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>March 2000</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of in vivo histologic response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cardiac Toxicity</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexrazoxane hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed newly diagnosed osteosarcoma&#xD;
&#xD;
               -  No more than 1 month since prior diagnostic biopsy&#xD;
&#xD;
               -  Nonmetastatic malignant high-grade osteosarcoma of bone&#xD;
&#xD;
               -  Histologically confirmed metastatic disease allowed&#xD;
&#xD;
               -  Unresectable primary disease allowed&#xD;
&#xD;
          -  No low-grade, parosteal, or periosteal osteosarcoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  25 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8.0 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  ALT less than 5 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times normal&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate greater than 70 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Shortening fraction at least 27% by echocardiogram or MUGA&#xD;
&#xD;
          -  Ejection fraction at least 45% by echocardiogram or MUGA&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent therapy with no evidence of progressive disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramzi Dagher, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Cancer Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 4, 2015</last_update_submitted>
  <last_update_submitted_qc>June 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <keyword>cardiac toxicity</keyword>
  <keyword>localized osteosarcoma</keyword>
  <keyword>metastatic osteosarcoma</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Dexrazoxane</mesh_term>
    <mesh_term>Razoxane</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

